


AFTER YOUR COVID-19 VACCINATION, TAKE THE NEXT STEP FOR YOUR LIVER HEALTH

Congratulations on receiving a vaccination for COVID-19!

This vaccination is an important step in protecting your health, including the condition of your liver. Patients with COVID-19 and chronic liver disease have higher rates of hospitalization and death, and COVID-19 itself can damage the liver.^{1,2,3} By receiving this vaccination, you've taken an essential step in protecting the health of your liver – but there are additional critical steps to take to protect this vital organ.

Healthy
Liver




What is NAFLD/NASH?

Your liver is part of your body's digestive system and plays a role in metabolism, or the process by which your body converts food into energy. If too much fat builds up in your liver, you can develop **nonalcoholic fatty liver disease** (NAFLD) which, left untreated, can lead to serious liver problems. **Nonalcoholic steatohepatitis** (NASH) is caused when that extra fat turns into inflammation (swelling in the liver) and fibrosis (scarring) of the liver. If severe enough, NASH can lead to cirrhosis or liver cancer, potentially requiring a liver transplant.

NAFLD/NASH can affect people of any age, including children. It is more common in people who live with certain conditions, including obesity (BMI>30) and conditions that may be related to obesity, such as type 2 diabetes, high blood pressure, or high cholesterol. NAFLD and NASH can have very few observable symptoms in the early stages, making it important to be screened by your physician or health care provider.

NAFLD/NASH is just one of more than 100 liver diseases. Some may be prevented by vaccines and some have treatments and cures. Patients with any liver disease, though, would benefit from proper management with a physician and increased research, just like the research that led to the COVID-19 vaccination you received today.



Up to 40 million people in the
U.S. are living with NASH.⁴

NAFLD/NASH is more common
in people who live with:

Obesity
Type 2 diabetes
High blood pressure
High cholesterol



What is the Next Step?

If you are at risk or diagnosed with NAFLD or NASH, you may consider getting a further check-up for your liver. There are some non-invasive ways to examine your liver and evaluate if you have too much fat and some scarring in your liver.

Call the number below to schedule an appointment. Your physician will discuss your options based on the results and may give you the option to participate in a clinical trial supporting patients with liver disease (clinical trials are research studies that help scientists discover new ways to prevent, detect, or treat disease).

Organization Name

Phone Number

Website

Brought to you by the City of
Global Liver Institute, and Summit Clinical Research.

Learn more about liver health from Global Liver Institute at www.GlobalLiver.org



Sources

¹ Hundt, M.A., Deng, Y., Ciarleglio, M.M., Nathanson, M.H. and Lim, J.K. (2020), Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network. *Hepatology*, 72: 1169-1176. <https://doi.org/10.1002/hep.31487>

² Wang, Q., Davis, P., and Xu, R. COVID-19 risk, disparities and outcomes in patients with chronic liver disease in the United States. *The Lancet*. Volume 31, 100688, January 1, 2021. Published: December 22, 2020. DOI: <https://doi.org/10.1016/j.eclinm.2020.100688>

³ Di Wu, Ting Shu, Xiaobo Yang, Jian-Xin Song, Mingliang Zhang, Chengye Yao, Wen Liu, Muhan Huang, Yuan Yu, Qingyu Yang, Tingju Zhu, Jiqian Xu, Jingfang Mu, Yaxin Wang, Hong Wang, Tang Tang, Yujie Ren, Yongran Wu, Shu-Hai Lin, Yang Qiu, Ding-Yu Zhang, You Shang, Xi Zhou. Plasma metabolomic and lipidomic alterations associated with COVID-19, *National Science Review*, Volume 7, Issue 7, July 2020, Pages 1157–1168, <https://doi.org/10.1093/nsr/nwaa086>

⁴ Spengler EK, Loomba R. Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. *Mayo Clinic Proceedings*. 2015;90(9):1233–1246. DOI: 10.1016/j.mayocp.2015.06.013